Abstract
Despite their diversity, global healthcare systems are increasingly converging
in the need and desire to contain costs of healthcare, and especially those
associated with pharmaceuticals. At the same time, Big Pharma are having to
contend with a dearth of invention, patent expirations, and increased generic
competition, among other factors undermining their profits. In this
environment, the importance of market access strategies, especially in terms
of pricing, reimbursement and parallel trade are rapidly gaining prominence.
Pharmaceutical and Biotech Market Entrance Strategies examines the key issues
that need to be addressed by pharmaceutical and biotechnology companies alike
in order to successfully achieve return on investment. The American, European
and Japanese markets are undergoing constant harmonisation changes, which are
leading to a globalisation of operating procedures and state intervention in
healthcare and drug cost containment. This trend has an important impact on
the overall environment facing the drug and biotechnology industry -- on the
one hand, facilitating access to a wider patient base but, on the other,
raising the stakes of key pricing and reimbursement decisions.
Pricing can no longer be considered separate to reimbursement, while parallel
trade threatens to undermine companies' wider regional efforts to achieve the
best price for their products. Lifecycle management issues increasingly
involve tailor-made medicines, pharmacogenomics and similar disciplines, as
well as greater co- operation within the industry and outside its boundaries.
This report examines these issues in great detail and helps the reader
navigate this increasingly complex field.
Pharmaceutical and Biotech Market Entrance Strategies provides the following:
- An overview of major market access strategies
- In-depth information regarding the pricing environments of the American,
European and Japanese pharmaceutical markets, comparing and contrasting their
major features with a view to securing the best approach
- In-depth information regarding reimbursement environments and market
strategies that are most suitable for a particular market
- Overview of parallel trade, including major responses to the threat by all
relevant players
- Overview of lifecycle management, identifying key factors for successful
product placement over time
- Examination of Latin American experience in terms of pricing strategies
and lessons that can be learned globally
Who should buy this report?
- Companies wishing to examine the most current pricing and regulatory
environments in major global markets, including different cost-containment
strategies used by governments and purse-holders.
- Companies interested in understanding the impact and implications of
parallel trade, with a view to minimising disadvantages to their products.
- Companies interested in understanding the wider opportunities and
challenges in the American, Japanese and European markets.
- Pharmaceutical and biotech companies wishing to identify both the threats
to products in these markets as well as the variety of profit maximisation
strategies outlined in this report.
| 
View Cart
